In this review:
Efficacy of masitinib in patients with progressive MS
Anti-CD20 DMTs are associated with worse COVID-19 outcomes
Disability trajectories in relapsing MS patients treated with early intensive or escalation treatment strategies
Pregnancy in a modern day MS cohort
Safety of alemtuzumab over 9 years in patients with non-MS autoimmunity
Risk estimates of fingolimod-related PML
Safety and efficacy of dimethyl fumarate over 13 years: final ENDORSE results
EMPhASIS: a phase 2 trial of vidofludimus calcium in RRMS
A retinoid-X receptor agonist promotes remyelination in RRMS
Impact of interrupting DMT for pregnancy in MS
Please login below to download this issue (PDF)